Exchange: HKSE Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
0.00% HKD0.0280
America/New_York / 2 mai 2024 @ 21:57
FUNDAMENTALS | |
---|---|
MarketCap: | 66.92 mill |
EPS: | -0.0700 |
P/E: | -0.400 |
Earnings Date: | Jun 28, 2024 |
SharesOutstanding: | 2 390.00 mill |
Avg Daily Volume: | 0.820 mill |
RATING 2024-05-02 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | ||
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | n/a | n/a | n/a | n/a | ||
Asset | n/a | n/a | n/a | n/a | ||
Debt | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.400 | sector: PE 34.76 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.400 | industry: PE 13.09 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
HKD 0.0260 - 0.0300 ( +/- 7.14%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | HKD0.0280 (0.00% ) |
Volume | 0.0500 mill |
Avg. Vol. | 0.820 mill |
% of Avg. Vol | 6.10 % |
Signal 1: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, distributes, and sells pharmaceutical products in the People's Republic of China. The company operates through Manufacturing, Trading, and Gene Development segments. It offers transfer factor oral solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels. In addition, it is involved in the marketing and distribution of imported pharmaceutical products, including Millibar for the treatment of high blood pressure; and development of oral insulin. Further, the company engages in the commercial exploitation and development of genome-related technology; provision of agency services; property investment business; and holding of gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.